Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD

Journal of Attention Disorders

Volumn 21, Issue 14, 2017, Pages 1180-1191

  Robb, Adelaide S ^a   Findling, Robert L ^b   Childress, Ann C ^c   Berry, Sally A ^d   Belden, Heidi W ^d   Wigal, Sharon B ^e  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Center for Psychiatry and Behavioral Medicine Inc   (United States)

^d PFIZER INC   (United States)

^e AVIDA Inc   (United States)

Author keywords

ADHD; laboratory school; math test; methylphenidate; randomized controlled trial

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ADMINISTRATION AND DOSAGE; ATTENTION DEFICIT DISORDER; CHILD; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; INSOMNIA; MALE; PSYCHOLOGICAL RATING SCALE; THERAPEUTIC USE; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 85032941067     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054714533191     Document Type: Article

References (25)

1. American Academy of Pediatrics. (2011). ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 128, 1007-1020.
2. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
3. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
4. Centers for Disease Control and Prevention. (2010). Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children—United States, 2003 and 2007. Morbidity and Mortality Weekly Report, 59, 1439-1443.
5. Childress A. C., Berry S. A., (2010). The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgraduate Medicine, 122, 35-41.
6. Coghill A., Banaschewski T., Lecendreux M., Soutullo C., Johnson M., Zuddas A... Squires L., (2013). European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 23, 1208-1218.
7. DuPaul G. J., Power T. J., Anastopoulos A. D., Reid R., (1998). ADHD rating scales-IV: Checklists, norms and clinical interpretation. New York, NY: Guilford.
8. Guy W., (1976). Clinical global impressions. In ECDEU assessment manual for psychopharmacology (pp. 218-222). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch.
9. Intuniv prescribing information. (2013). Wayne, PA: Shire US.
10. Kapvay prescribing information. (2013). Florham Park, NJ: Shionogi.
11. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P... Ryan N., (1997). Schedule for affective disorders and schizophrenia for school-age children–present and lifetime version (K-SADS- PL): Initial reliability and validity data. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 980-988.
12. Kessler R. C., Adler L., Barkley R., Biederman J., Conners C. K., Demler O... Zaslavsky A. M., (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. American Journal of Psychiatry, 163, 716-723.
13. McGough J. J., Wigal S. B., Abikoff H., Turnbow J. M., Posner K., Moon E., (2006). A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. Journal of Attention Disorders, 9, 476-485.
14. National Heart, Lung, and Blood Institute, National Institutes of Health. (2005). The fourth report on the diagnosis, evaluation, and treatment of blood pressure in children and adolescents (NIH Publication No. 05-5267). Retrieved from http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf
15. National Institute of Mental Health, National Institutes of Health. (2012). Attention deficit hyperactivity disorder. Retrieved from http://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml
16. Pelham W. E., Gnagy E. M., Burrows-Maclean L., Williams A., Fabiano G. A., Morrisey S. M...Morse G. D., (2001). Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics, 107, E105.
17. Pelham W. E., Waxmonsky J. G., Schentag J., Ballow C. H., Panahon C. J., Gnagy E. M...González M. A., (2011). Efficacy of a methylphenidate transdermal system versus t.i.d. methylphenidate in a laboratory setting. Journal of Attention Disorders, 15, 28-35.
18. Pliszka S. R., Bernet W., Bukstein O., Walter H. J., Arnold V., Beitchman J... Stock S., (2007). The American Academy of Child and Adolescent Psychiatry (AACAP) Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 894-921.
19. Posner K., Oquendo M. A., Gould M., Stanley B., Davies M., (2007). Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. American Journal of Psychiatry, 164, 1035-1043.
20. Quillivant XR prescribing information. (2013). New York, NY: Pfizer.
21. Quinn D., Wigal S., Swanson J., Hirsch S., Ottolini Y., Dariani M... Cooper T., (2004). Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 43, 1422-1429.
22. Strattera prescribing information. (2013). Indianapolis, IN: Eli Lilly.
23. Wigal S. B., Childress A. C., Belden H. W., Berry S. A., (2013). NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared to placebo in a laboratory classroom study. Journal of Child and Adolescent Psychopharmacology, 23, 1-8.
24. Wigal S. B., Wigal T. L., (2006). The laboratory school protocol: Its origin, use, and new applications. Journal of Attention Disorders, 10, 92-111.
25. Wigal S. B., Wigal T., Schuck S., Brams M., Williamson D., Armstrong R. B., Starr H. L., (2011). Academic, behavioral, and cognitive effects of OROS methylphenidate on older children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21, 121-131.